Literature DB >> 20701404

Angiotensin receptor blockers and the risk of malignancy: a note of caution.

Domenic A Sica.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20701404     DOI： 10.2165/11532450-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  11 in total

1.  Angiotensin-receptor blockade, cancer, and concerns.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael A Weber
Journal:  Lancet Oncol       Date:  2010-09       Impact factor: 41.316

Review 2.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

Authors:  Ilke Sipahi; Sara M Debanne; Douglas Y Rowland; Daniel I Simon; James C Fang
Journal:  Lancet Oncol       Date:  2010-06-11       Impact factor: 41.316

Review 3.  Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies.

Authors:  M Pahor; C D Furberg
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 3.923

Review 4.  Antihypertensive therapy and the risk of malignancies.

Authors:  E Grossman; F H Messerli; U Goldbourt
Journal:  Eur Heart J       Date:  2001-08       Impact factor: 29.983

5.  Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Authors:  Frans H H Leenen; Chuke E Nwachuku; Henry R Black; William C Cushman; Barry R Davis; Lara M Simpson; Michael H Alderman; Steven A Atlas; Jan N Basile; Aloysius B Cuyjet; Richard Dart; James V Felicetta; Richard H Grimm; L Julian Haywood; Syed Z A Jafri; Michael A Proschan; Udho Thadani; Paul K Whelton; Jackson T Wright
Journal:  Hypertension       Date:  2006-07-24       Impact factor: 10.190

6.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

7.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

Authors:  S Yusuf; B Pitt; C E Davis; W B Hood; J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

Authors:  G Maschio; D Alberti; G Janin; F Locatelli; J F Mann; M Motolese; C Ponticelli; E Ritz; P Zucchelli
Journal:  N Engl J Med       Date:  1996-04-11       Impact factor: 91.245

9.  Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials.

Authors:  Craig I Coleman; William L Baker; Jeffrey Kluger; C Michael White
Journal:  J Hypertens       Date:  2008-04       Impact factor: 4.844

Review 10.  Antihypertensive therapy and cancer risk.

Authors:  D C Felmeden; G Y Lip
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228
View more
  1 in total

1.  Angiotensin and systems thinking: wrapping your mind around the big picture.

Authors:  Gary Robert Smith
Journal:  Ochsner J       Date:  2013
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.